Drugs / interferon alfa-1b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00276536 | Jan 2001 → Jan 2004 | breast cancer, kidney cancer, melanoma, plasma cell myeloma +1 | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00278174 | Feb 2005 → Apr 2007 | kidney cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interferon alfa-1b | “interferon alfa-1b (IFN-α1b) in patients with stage IV solid tumors, lymphoma, or myeloma” NCT00276536 ↗1“Patients receive interferon alfa-1b subcutaneously daily.” NCT00278174 ↗ |
| Known as | IFN-α1b | “interferon alfa-1b (IFN-α1b)” NCT00276536 ↗ |
| Modality | Protein / enzyme biologic | “Biological: recombinant interferon alpha-1b” NCT00276536 ↗ |
| Route | Subcutaneous | “given daily by subcutaneous injection” NCT00276536 ↗ |